Veradigm, Inc.

As of July 8, 2024, Veradigm, Inc. is considered overvalued with a high P/E ratio of 142 and significant underperformance compared to the S&P 500, leading to a valuation downgrade from expensive to does not qualify.

As of May 4, 2023, Veradigm, Inc. is considered overvalued with a high P/E ratio of 142 and poor financial performance metrics, including a ROCE of 2.68% and a year-to-date return of -53.95%, compared to the S&P 500's 2.44%.

As of May 30, 2025, Veradigm, Inc. shows a mildly bearish trend due to daily moving averages and weekly Bollinger Bands indicating bearishness, despite some mildly bullish signals from the weekly MACD and KST.

As of March 2022, Veradigm, Inc.'s management team includes Independent Chairman Mr. Michael Klayko, CEO Mr. Paul Black, and Directors Beth Altman, Carol Zierhoffer, Mara Aspinall, P. Gregory Garrison, and Jonathan Judge. The team features a blend of executive leadership and independent directors.

Veradigm, Inc. is a healthcare IT solutions provider in the small-cap market, reporting net sales of $156 million and a net loss of $27 million as of December 2022. The company has a market cap of $1.42 billion and key metrics include a P/E ratio of 142 and a return on equity of 0.99%.

As of Jun 18, Veradigm, Inc. has a market capitalization of 1,424.30 million, with net sales of 601.70 million and a net profit of 5.78 million over the latest four quarters.